New Jersey

Merck earnings down, but cancer drug collaboration may help

Merck earnings down, but cancer drug collaboration may help

New Jersey based drug-maker Merck is reporting both a dip in profits and what could be a lucrative collaboration.

The company reported a 14 percent decline in fourth-quarter profits.

Competition from generic drugs is continuing to cut into the company's sales.

But things could be looking up for Merck; the company announced an alliance with three other drugmakers to test an experimental cancer drug.

The drug is meant to restore the immune system's natural ability to spot and target cancer cells.

DISCLAIMER FOR COMMENTS: The views expressed by public comments are not those of this company or its affiliated companies. Please note by clicking on "Post" you acknowledge that you have read the TERMS OF USE  and the comment you are posting is in compliance with such terms. Your comments may be used on air. Be polite. Inappropriate posts or posts containing offsite links may be removed by the moderator.

Allentown, PA 18102




  • %

This Week's Circulars

Latest from the newsroom